nasopharyngeal carcinoma
Conditions
Interventions
treatment-group: Docetaxel plus Cisplatin Induction Chemotherapy followed by Cisplatin Concurrent Chemoradiotherapy and Docetaxel plus Cisplatin Adjuvant Chemotherapy
Sponsors
Huizhou Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients must give signed informed consent; 2. Male or female aged between 18-60 years old; 3. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III; TNM stage; T3-4/N2-3 or the level of Plasma Epstein–Barr Virus DNA >=4000copy/ml after concurrent chemoradiation therapy 4. KPS>=70 score 5. With normal hematopoietic function test: ANC>=2*10^9/L, PLT >=100*10^9/L and HGB >=9g/dLWith normal liver function test TBIL=80 mL/min.
Exclusion criteria
Exclusion criteria: 1. With a history of other malignant tumors; 2. With history of anti-tumor treamentincluding chemotherapy,radiotherapy,surgery; 3. Newly diagnosed with metastasis; 4. Pregnant or lactating women; 5. Known to be likely allergic to chemotherapy drug being used.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| distant failure-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival rate;Local-regional control rate;progression-free survival rate;treatmen-related toxicity; | — |
Countries
China
Contacts
Public ContactXian Yuan
Huizhou Municipal Hospital
Outcome results
None listed